Adenovirus Hexon and Penton peptide-HLA complexes (AdV pHLA)

Peptide–HLA complexes derived from adenoviral Hexon and Penton antigens are the primary molecular targets for the cellular immune response against human adenovirus (HAdV) (Source: NIH, Springer). Hexon and Penton are the major structural proteins of the icosahedral viral capsid and contain highly conserved, immunodominant epitopes that are processed and presented on the surface of infected cells by Human Leukocyte Antigen (HLA) molecules (Source: NIH, ResearchGate). These complexes are recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T cells and CD4+ helper T cells, triggering an immune response that leads to the clearance of the virus (Source: NIH, PubMed). In immunocompromised individuals, such as those undergoing hematopoietic stem cell transplantation (HSCT), the lack of these specific T cells can lead to life-threatening disseminated adenovirus infections (Source: NIH, Transplant Cell Therapy). Consequently, these pHLA complexes serve as critical targets for adoptive T-cell therapies, such as Posoleucel (Viralym-M), which utilize donor-derived or off-the-shelf T cells to restore antiviral immunity (Source: ElevateBio, AlloVir). Therapeutic strategies focusing on these targets aim to provide precise viral control while minimizing off-target effects like graft-versus-host disease (Source: NIH, Trends in Pharmacological Sciences).

Other names

Adenoviral Hexon/Penton epitopesAdenovirus capsid antigen-HLA complexesAdV Hexon and Penton pHLAPeptide-HLA complexes derived from adenoviral Hexon and Penton antigens

T-cell receptor (TCR) mediated recognition of the peptide-HLA complex, leading to T-cell activation and cytotoxic lysis of adenovirus-infected cells.